2023
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
Lu L, Ma W, Johnson C, Khan S, Irwin M, Pusztai L. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine 2023, 41: 2073-2083. PMID: 36813666, PMCID: PMC10064809, DOI: 10.1016/j.vaccine.2023.02.048.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmCA-125 AntigenCancer VaccinesEpitopes, T-LymphocyteFemaleHumansMRNA VaccinesOvarian NeoplasmsConceptsMRNA vaccinesOvarian cancerT cell responsesMutation-derived neoantigensT cell epitopesSARS-CoV-2Multiple neoantigensCytotoxic CD8Dendritic cellsCA 125Cancer vaccinesPatient survivalImmune responseCell epitopesNeoepitope peptidesNeoantigensVaccineCell responsesCancerBreastReverse vaccinologyCD8CD40LIFNNeoepitopes
2011
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation
Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. European Journal Of Cancer 2011, 48: 12-23. PMID: 21741824, DOI: 10.1016/j.ejca.2011.06.025.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlgorithmsBreast NeoplasmsCancer VaccinesCarcinomaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHealth Status IndicatorsHumansImmunotherapyMelanoma-Specific AntigensMicroarray AnalysisMiddle AgedReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneConceptsTriple-negative breast cancerCancer/testis antigensNegative breast cancerBreast cancerTestis antigensMelanoma antigen family AHuman epidermal growth factor receptor 2 (HER2) receptorsImmune response augmentationImmune-stimulatory drugsMAGE-A antigensHigh expressionLymph node statusDistinct disease subsetsLess prognostic valueHigher MAGELow MAGEWorse survivalNode statusPoor prognosisPrognostic valueDisease subsetsImmune infiltrationPredictive markerImmune metagenesImmune response